Amag pharmaceuticals, inc. (AMAG)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Cash paid for interest

-

-

-

-

28,014

2,500

-

-

-

-

-

-

Cash flows from operating activities:
Net loss

-466,456

-65,761

-199,228

-2,483

32,779

135,817

-9,602

-16,750

-77,069

-81,153

-93,351

-71,647

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization

27,324

172,223

155,538

99,886

69,103

6,984

3,085

3,084

2,536

2,405

1,913

1,497

Asset Impairment Charges

232,300

0

319,246

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

19,663

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

0

0

-

-

-

-

-

-

Provision for bad debt expense

0

678

3,852

3,209

0

0

-

-

-

-

-

-

Amortization of premium/discount on purchased securities

95

-87

-302

-624

-2,152

-2,080

-2,758

-2,808

-3,639

-1,679

-490

-482

Impairment loss on assets held for sale

-

-

-

-

-

-

-

1,100

-

-

-

-

Write-down of inventory

19,800

5,176

0

-

1,235

1,309

2,175

1,822

685

-

-

-

Non-cash equity-based compensation expense

19,198

19,916

23,664

22,543

17,237

8,625

8,004

7,024

10,038

14,523

15,421

8,037

Gain (Loss) on Extinguishment of Debt

0

-35,922

-10,926

0

-

-

-

-

-

-

-

-

Non-cash loss on debt extinguishment

-

-

-

-

6,426

-

-

-

-

-

-

-

Non-cash IPR&D expense

18,029

0

945

0

0

-

-

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-

-

0

-

-

-

-

-

-

Amortization of debt discount and debt issuance costs

15,242

15,658

14,395

12,105

11,379

6,870

-

-

-

-

-

-

Gains on marketable securities, net

265

1

-70

-38

-

-

-

-

-

-

-

-

Fair value adjustment of settlement rights

-

-

-

-

-

-

-

-

-

-788

-778

1,566

(Loss) gain on sale of investments, net

-

-

-

-

14

114

40

-1,466

-193

408

942

-3,024

Change in fair value of contingent consideration

-270

-49,607

-47,686

25,683

4,271

-681

1,074

-

-

-

-

-

Deferred income taxes

404

41,166

-178,421

7,279

-

-

-

-

-

-

-

-

Non-cash lease expense

2,725

0

0

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

5,007

-153,159

-

-

-

-

-

-

(Gain) loss on disposal of fixed assets

0

99

-265

-

-

-

-

-

-

-

-

-

Non-cash income tax benefit

-

-

-

-

-

-

-

-854

-1,170

-481

-1,089

-

Gain on sale of assets

-

-

-

0

0

103

924

-

-

-

-

-

Gain (Loss) on Disposition of Business

0

87,076

0

0

-

-

-

-

-

-

-

-

Increase (Decrease) In Transaction Costs

0

14,111

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

18,816

-16,995

14,978

9,906

36,913

-3,588

432

478

147

-21,565

26,942

185

Inventories

19,253

454

2,331

2,355

5,237

1,360

1,040

-4,069

-821

6,675

9,063

-288

Receivable from collaboration

-

-

-

-428

-4,090

4,239

15

-165

-13

441

-

-

Prepaid and other current assets

113

6,097

2,222

-4,095

-4,034

-2,331

-2,817

-75

-1,661

2,477

762

1,910

Other long-term assets

-

-

-

-

-

-

1,964

-

-

-

-

-

Accounts payable and accrued expenses

52,747

-32,568

16,834

49,037

7,876

10,694

-5,730

-12,195

1,698

2,745

13,215

6,596

Deferred revenues

-6,400

8,658

17,080

24,522

-

-

-

-

-

-

-

-

Deferred revenues

-

-

-

-

-22,197

-8,384

-6,694

7,912

-6,353

46,697

9,682

42

Payment of contingent consideration in excess of acquisition date fair value

0

0

10,432

8,116

0

0

-

-

-

-

-

-

Repayment of term loan attributable to original issue discount

-

-

-

-

-12,491

0

-

-

-

-

-

-

Other assets and liabilities

1,800

-95

1,223

30

-7,244

-1,156

-

-

-

-

-

-

Net cash used in operating activities

-125,696

60,800

106,596

246,222

95,981

11,414

-

-

-

-

-

-52,336

Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities

98,321

85,342

294,957

127,479

-

-

-

-

-

-

-

-

Purchase of marketable securities

14,815

89,956

127,249

194,723

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-246

-405

-349

-294

-68

3,006

Total adjustments

-

-

-

-

-

-

-

15,593

13,265

79,626

2,633

19,311

Net cash provided by operating activities

-

-

-

-

-

-

-6,774

-1,157

-63,804

-1,527

-90,718

-

Acquisition of Lumara Health, net of acquired cash

-

-

-

-

-562

595,602

-

-

-

-

-

-

Acquisition of CBR, net

-

-

-

-

682,356

0

-

-

-

-

-

-

Proceeds from sales or maturities of investments

-

-

-

-

208,966

223,568

106,030

133,061

141,095

160,079

74,543

233,194

Purchase of investments

-

-

-

-

424,759

63,747

115,046

149,406

126,585

262,597

310

137,438

Acquisition of intangible asset

-

-

-

0

0

-

-

-

-

-

-

-

Proceeds from the sale of the CBR business

0

519,303

0

0

-

-

-

-

-

-

-

-

Note receivable

0

10,000

0

-

-

-

-

-

-

-

-

-

Note receivable

-

-

-

0

-

-

-

-

-

-

-

-

Change in restricted cash

-

-

-

-

195

-2,883

2,823

-

-

-

-61

426

Capital expenditures

2,544

2,534

8,988

5,460

-

-

-

47

507

1,223

2,835

8,178

Capital expenditures

-

-

-

-

1,259

44

-1,338

-

-

-

-

-

Net cash (used in) provided by investing activities

20,962

502,155

102,920

-72,704

-899,041

-432,942

-13,935

-16,392

14,003

-103,741

71,459

87,152

Cash flows from financing activities:
Long-term debt principal payments

0

475,000

353,125

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses

-

-

-

-

407,477

0

-

-

-

165,559

-

-

Long-term debt principal payments

-

-

-

17,502

327,509

0

-

-

-

-

-

-

Proceeds from long-term debt

-

-

-

-

834,750

527,509

-

-

-

-

-

-

Proceeds from Convertible Debt

0

0

320,000

0

0

-

-

-

-

-

-

-

Payments to settle convertible notes

21,417

0

191,730

0

0

-

-

-

-

-

-

-

Payment for Debt Extinguishment or Debt Prepayment Cost

0

28,054

625

0

-

-

-

-

-

-

-

-

Proceeds to settle warrants

0

0

323

0

0

-

-

-

-

-

-

-

Payments of Debt Issuance Costs

0

0

9,553

0

10,004

7,760

-

-

-

-

-

-

Payments of contingent consideration

72

119

39,793

92,130

456

270

51

-

-

-

-

-

Proceeds from issuance of warrants

-

-

-

-

-

25,620

-

-

-

-

-

-

Purchase of convertible bond hedges

-

-

-

-

-

39,760

-

-

-

-

-

-

Payment to former CBR shareholders

-

-

-

-

7,195

0

-

-

-

-

-

-

Payments for repurchases of common stock

13,730

0

19,466

20,000

0

0

-

-

-

-

-

-

Proceeds from the issuance of common stock under the ESPP

1,506

0

0

-

-

-

-

-

-

-

-

-

Proceeds from the issuance and exercise of common stock options

-

-

-

-

15,406

-

-

-

-

-

-

-

Proceeds from the exercise of common stock options

30

3,881

3,021

3,885

-

8,499

1,277

98

121

1,337

4,047

763

Proceeds from the issuance of common stock under ESPP

-

-

-

-

-

0

176

270

508

892

1,156

393

Payments of employee tax withholding related to equity-based compensation

1,830

2,682

2,696

2,171

0

0

-

-

-

-

-

-

Net cash used in financing activities

-35,513

-501,974

-293,644

-127,918

912,469

513,838

1,402

368

629

167,788

5,203

1,156

Net decrease in cash, cash equivalents, and restricted cash

-140,247

60,981

-84,128

45,600

109,409

92,310

-19,307

-17,181

-49,172

62,520

-14,056

35,972

Supplemental data for cash flow information:
Cash (refunded) paid for taxes

-202

5,345

5,296

-

-

-

-

-

-

-

-

-

Cash paid for taxes

-

-

-

5,309

2,373

0

-

-

-

-

-

-

Cash paid for interest

10,667

48,757

56,959

62,381

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Settlement of note receivable in connection with Perosphere acquisition

10,000

0

0

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities

18,455

-

-

-

-

-

-

-

-

-

-

-

Stock Issued During Period, Value, Purchase of Assets

-

-

13,500

-

-

-

-

-

-

-

-

-

Accrued construction in progress

-

-

-

-

-

-

-

228

-

-

272

-

Fair value of common stock issued in connection with the Lumara Health acquisition

-

-

-

-

-

111,964

-

-

-

-

-

-

Investments reclassified to trading, at fair value

-

-

-

-

-

-

-

-

-

-

-

7,650

Vyleesi Products
Acquisition of intangible asset

60,000

0

0

-

-

-

-

-

-

-

-

-

Intrarosa
Acquisition of intangible asset

0

0

55,800

-

-

-

-

-

-

-

-

-

Endoceutics, Inc.
Stock Issued During Period, Value, Purchase of Assets

0

0

12,555

0

-

-

-

-

-

-

-

-